Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Pyridostigmine tablets

Registration Number: NCT00518154

Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Brief Summary: The purpose of this study is to determine whether the addition of Pyridostigmine to Highly Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant patients in which viral load diminishes, but T-cell levels remain low after the initiation of treatment.

Detailed Description: In HIV-1 infected patients, HAART suppresses viral replication, reflected by a reduced viral load, and a recovery in the frequency of CD4+ T-cells. The latter is associated with a reduced risk for developing opportunistic infectious diseases, and death. T-cell recovery, however, is highly variable within individuals, suggesting that virological eradication is but one factor of it.

A phenomenon known as Immune Discordance has been well known. It reflects a subpopulation -as high as 30% of patients- in whom there is an adequate suppression of viral replication, but CD4+ cell levels rise modestly (below safety levels). In this setting, patients remain susceptible to develop opportunistic infections, have disease progression, and die. Various mechanisms have been proposed, but one common factor is enhanced CD4+-cell activation, leading to cell dysfunction and apoptosis.

It is known that an inflammatory response is able to activate the anti-inflammatory cholinergic pathway, in which acetylcholine (ACh) is released and in turn activates nicotinic receptors in macrophages. The result is a diminished synthesis of inflammatory cytokines such as TNF-α, and IL-1. We have recently shown in an ex-vivo, proof-of-concept study carried in HIV-infected subjects in early phases of the infection (not requiring specific treatment) that Pyridostigmine diminishes CD4+-cell activation and an increase in the subpopulation of regulatory T-cells (T-reg).

Pyridostigmine, an ACh-esterase inhibitor, has been shown to be safe in other populations, including healthy Gulf War military personnel, and patients with Myasthenia Gravis. Its hypothetical effect is by reducing the degrading rate of the naturally occurring ACh (released by the vagus nerve) by the enzyme ACh-esterase. This in turn enhances its coupling to nicotinic receptors in macrophages that, according to our previous study (unpublished data), improves the T-cell milieu, diminishes T-cell activation (a well known trigger for apoptosis), and enhances T-reg proliferation.

The purpose of this study is to determine whether the addition of Pyridostigmine to Highly Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant patients in which viral load diminishes, but T-cell levels remain low after the initiation of treatment.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 7

Inclusion Criteria

HIV-1 infected subjects 18 years of age or older
Receiving HAART for at least two years
At least a viral load determination per year since HAART initiation, all undetectable
Patient's status is Immunological Non Responder (InR), that is, his or her viral load is reduced, but CD4+ cell count has not raised accordingly
Current viral load: undetectable
Patient agrees and signs informed consent

Exclusion Criteria

Concomitant active infectious or neoplastic disease
History of new AIDS-defining events during HAART
Pregnancy or breast-feeding
Patients who have been subjects of an investigational agent, chemotherapy or radiotherapy within the previous 28 days
Subjects requiring treatment for Tuberculosis
Subjects unable to follow, or comply with the protocol interventions
Subjects receiving immunosuppressive treatment, including corticosteroids

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A	Pyridostigmine tablets	Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment

Primary Outcome Measures

Name	Time	Method
CD4+ Cell Count Change Between Basal and Week 16 of Additive Treatment	16 weeks after initiation of pyridostigmine	Change in total CD4+ T-cell number from baseline to addition of pyridostigmine

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (2): Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
🇲🇽
Tlalpan, Ciudad De México, Mexico
Sergio I. Valdés-Ferrer
🇲🇽
Mexico City, DF, Mexico